Aslan Pharmaceuticals Ltd ADR
(ASLN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2017 | 09-2017 | 06-2017 | 03-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -39,892 | -25,530 | -17,557 | -8,080 | -9,049 |
| Depreciation Amortization | 210 | 154 | 96 | 41 | 76 |
| Accounts receivable | 1,294 | 1,386 | 1,386 | 1,348 | N/A |
| Accounts payable and accrued liabilities | 1,621 | -1,335 | 717 | 1,282 | N/A |
| Other Working Capital | 3,292 | -208 | 1,222 | 1,452 | 1,472 |
| Other Operating Activity | -642 | 953 | -1,317 | -2,265 | 1,712 |
| Operating Cash Flow | $-34,117 | $-24,580 | $-15,454 | $-6,222 | $-5,789 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -291 | -284 | -270 | -16 | -374 |
| Purchase Of Investment | -36 | -31 | -44 | -52 | N/A |
| Purchase Sale Intangibles | -9 | -9 | N/A | N/A | N/A |
| Other Investing Activity | -9 | -9 | 0 | 0 | -149 |
| Investing Cash Flow | $-336 | $-324 | $-314 | $-68 | $-523 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 229 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 33,061 | 32,984 | 32,984 | N/A | N/A |
| Other Financing Activity | 0 | 0 | 0 | 0 | 30,987 |
| Financing Cash Flow | $33,290 | $32,984 | $32,984 | $N/A | $30,987 |
| Exchange Rate Effect | N/A | -2,504 | -2,468 | -2,849 | 0 |
| Beginning Cash Position | 51,737 | 55,406 | 55,406 | 53,900 | 27,062 |
| End Cash Position | 50,573 | 60,982 | 70,154 | 44,760 | 51,737 |
| Net Cash Flow | $-1,164 | $5,576 | $14,748 | $-9,140 | $24,675 |
| Free Cash Flow | |||||
| Operating Cash Flow | -34,117 | -24,580 | -15,454 | -6,222 | -5,789 |
| Capital Expenditure | -291 | -284 | -270 | -16 | N/A |
| Free Cash Flow | -34,408 | -24,864 | -15,724 | -6,238 | -5,789 |